CHA
MRNA icon

Carmichael Hill & Associates’s Moderna MRNA Stock Holding History

Carmichael Hill & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.81K Buy
57
+5
+10% +$459 ﹤0.01% 681
2024
Q2 		$6.17K Buy
52
+8
+18% +$1.01K ﹤0.01% 622
2024
Q1 		$4.69K Hold
44
– – ﹤0.01% 640
2023
Q4 		$4.38K Sell
44
-37
-46% -$3.11K ﹤0.01% 659
2023
Q3 		$8.37K Hold
81
– – ﹤0.01% 584
2023
Q2 		$9.84K Hold
81
– – ﹤0.01% 562
2023
Q1 		$12.4K Hold
81
– – 0.01% 521
2022
Q4 		$14.5K Hold
81
– – 0.01% 502
2022
Q3 		$10K Hold
81
– – 0.01% 566
2022
Q2 		$12K Hold
81
– – 0.01% 525
2022
Q1 		$14K Sell
81
-25
-24% -$4.21K 0.01% 544
2021
Q4 		$27K Sell
106
-13
-11% -$3.8K 0.01% 477
2021
Q3 		$46K Buy
119
+15
+14% +$5.53K 0.02% 364
2021
Q2 		$24K Buy
104
+47
+82% +$8.4K 0.01% 492
2021
Q1 		$7K Hold
57
– – ﹤0.01% 623
2020
Q4 		$6K Sell
57
-43
-43% -$4.35K ﹤0.01% 614
2020
Q3 		$7K Sell
100
-100
-50% -$6.97K ﹤0.01% 570
2020
Q2 		$13K Buy
+200
New +$11K 0.01% 469

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carmichael Hill & Associates's MRNA Position: Q3 2024 in Review

Carmichael Hill & Associates increased its Moderna (MRNA) stake by 9.6% in Q3 2024, buying an estimated $459 and bringing the position to 57 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #681.

Carmichael Hill & Associates first reported a position in MRNA in Q2 2020 and has held it in 18 quarters since. The position peaked at $46K in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Carmichael Hill & Associates held 57 shares of Moderna worth $3.81K as of Q3 2024.
  • Carmichael Hill & Associates bought 5 Moderna shares in Q3 2024, an estimated $459.
  • Moderna made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #681 holding.
  • Carmichael Hill & Associates first reported a position in Moderna in Q2 2020 and has held it in 18 quarters since.
  • Carmichael Hill & Associates's Moderna position peaked at $46K in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.